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Abstract
Routine HIV viral load (VL) monitoring is the standard of care for persons receiving antiretro-
viral therapy (ART) in developed countries. Although the World Health Organization recom-
mends annual VL monitoring of patients on ART, recognizing difficulties in conducting
routine VL testing, the WHO continues to recommend targeted VL testing to confirm treat-
ment failure for persons who meet selected immunologic and clinical criteria. Studies have
measured positive predictive value (PPV), negative predictive value, sensitivity and speci-
ficity of these criteria among patients receiving first-line ART but not specifically among
those on second-line or subsequent regimens. Between 2008 and 2011, adult ART patients
in Nyanza, Kenya who met national clinical or immunologic criteria for treatment failure
received targeted VL testing. We calculated PPV and 95% confidence intervals (CI) of
these criteria to detect virologic treatment failure among patients receiving a) first-line ART,
b) second/subsequent ART, and c) any regimen. Of 12,134 patient specimens tested,
2,874 (23.7%) were virologically confirmed as treatment failures. The PPV for 2,834 first-
line ART patients who met either the clinical or immunologic criteria for treatment failure
was 34.4% (95% CI 33.2–35.7), 33.1% (95% CI 24.7–42.3) for the 40 patients on second-
line/subsequent regimens, and 33.4% (95% CI 33.1–35.6) for any ART. PPV, regardless of
criteria, for first-line ART patients was lowest among patients over 44 years old and highest
for patients aged 15 to 34 years. PPV of immunological and clinical criteria for correctly
identifying treatment failure was similarly low for adult patients receiving either first-line or
second-line/subsequent ART regimens. Our data confirm the inadequacy of clinical and
immunologic criteria to correctly identify treatment failure and support the implementation of
routine VL testing.
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Introduction
In sub-Saharan Africa, there are an estimated 22.1 million adults aged 15 years and above living
with HIV and 1.4 million of these reside in Kenya, the country with the fourth highest number
of infected persons worldwide [1]. According to service delivery data, the number of persons
receiving antiretroviral therapy (ART) in Kenya has dramatically increased from 5,000 in 2003
to more than 500,000 at the end of 2011 [2]. In Nyanza, a region in Western Kenya bordering
Lake Victoria, HIV prevalence among adults and adolescents aged 15–64 years in 2012 was
15.1%, the highest in the country [3].
A concern for persons on ART, particularly in resource-constrained areas, is the develop-
ment of treatment failure followed by the change to more expensive regimens. In developed
countries, identification of treatment failure is done through routine viral load (VL) testing.
However, the costs, small number of laboratories with expertise in measuring VL, and difficulty
with reliable transport of specimens, has greatly limited the use of routine VL testing in most
resource-limited settings. Although the World Health Organization (WHO) recently adopted
new recommendations for VL testing as the preferred routine method to monitor patients on
ART, recognizing that this may not be feasible in all settings, the WHO continues to recom-
mend the use of CD4 and clinical monitoring to diagnose treatment failure and VL testing to
confirm failure in order avoid unnecessary changes in regimens [4]. The preference for routine
VL monitoring over clinical and immunologic criteria to detect treatment failure comes from
studies that have demonstrated low positive and negative predictive values of these criteria to
detect failure [5–9]. However, none of these studies specifically evaluated the performance of
these criteria among patients who were receiving second-line or subsequent ART regimens. It
is possible that in resource-limited settings the absence of information on the predictive value
of clinical and immunologic criteria for identifying treatment failure among patients who have
changed regimens may lead to an overreliance on these criteria rather than support for routine
VL monitoring.
In 2008, targeted VL testing was initiated in Nyanza region for patients on first-line or sec-
ond-line ART regimens suspected to be failing treatment and meeting national immunological
or clinical criteria for treatment failure adopted fromWHO. We measured the positive predic-
tive value (PPV) of immunological and clinical criteria for treatment failure among adult
patients on first-line, second-line or other ART regimens. In June 2012, the Kenya national
HIV treatment guidelines were updated, adding routine VL testing at 6 and 12 months after
ART initiation and thereafter one VL test per year, aligning with the 2013 WHO treatment
guidelines [4, 10]. However, at the time of writing this paper, routine VL monitoring had not
yet been implemented. This analysis is therefore based on the 2008 national treatment guid-
ance for targeted VL testing.
Methods
Study setting, population, and measures
Targeted VL testing was offered at 180 of the 600 health facilities in Nyanza that provided HIV
care and treatment services as of the end of 2011. These facilities included dispensaries, health
centers, sub-district hospitals, district hospitals, provincial, and referral hospitals. The study
period was from September 2008 to December 2011.
The Kenya National AIDS and Sexually Transmitted Disease Control Program established
criteria for ART failure based on the WHO clinical and immunologic criteria [11]. Adult
patients who had been receiving ART for at least six months and had a new or recurrent WHO
clinical stage 3 or 4 condition, new or recurrent papular pruritic eruptions, a decline in the
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CD4 cell count or percentage to baseline, a decline of more than 50% in the CD4 count or per-
centage, or patients who had received more than 12 months of ART and failed to demonstrate
an increase greater than or equal to 50 CD4 cells/μL or had CD4 cell counts that remained
under 100 cells/μL were eligible for VL testing to confirm the need to change regimens.
To ensure adherence to VL testing guidelines, standardized laboratory request forms that
included the indications for VL testing and job aids were developed in 2008 and revised in
2009. Health workers were trained to recognize the clinical and immunologic criteria for tar-
geted VL testing, complete the laboratory requisition form, and interpret the test results.
Additionally, the mechanism to transport the specimens and receive results were developed
prior to implementation of targeted VL testing. The laboratory requisition form included
patient demographic information, facility where patient was receiving care, the indications for
VL testing, current and past ART regimens, and CD4 test dates and results. Note that only the
clinician documented indication for VL testing was used regardless of the CD4 test results
included on the laboratory requisition. Specimens collected from patients with reported poor
adherence two weeks prior to VL testing, active infections, including newly diagnosed tuber-
culosis or fever, were not tested since these conditions may increase or cause transient VL
increase.
This analysis includes patients aged 15 years and above for whom the indication for testing
was documented on the requisition form. Because VL testing was used to routinely monitor
ART virologic response among pregnant women who did not have clinical or immunologic cri-
teria, we excluded this sub-population from the analysis (Fig 1). We used the CD4 test result
that was closest to the date the VL specimen was obtained, provided that it occurred within 90
days prior to and not more than seven days after the VL specimen was obtained. Duration on
ART was calculated from the date of the current ART regimen initiation to the date of speci-
men collection for all patients. Quantitative HIV RNA testing was conducted on plasma sam-
ples at the Kenya Medical Research Institute laboratory in Nyanza using the Roche COBAS
Amplicor™ 1.5 [12].
Statistical analysis
We calculated the PPV and corresponding 95% exact binomial confidence intervals of the clin-
ical and immunologic criteria to identify virologic failure using Stata diagt command. Positive
predictive value was calculated as the number of persons who met the clinical or immunologic
criteria for viral load testing divided by the total number of persons with virologic failure
Table 1. We defined failure using the current Kenyan andWHO definition of treatment failure
(HIV RNA concentration equal to or above 1000 copies/mL) from a single specimen. We cal-
culated separate PPVs for a) any of the criteria, b) any clinical criterion, and c) any immuno-
logic criterion among patients receiving i) any regimen, ii) any first-line regimen, and iii) any
second-line or other subsequent regimen. These analyses were categorized by age at VL testing,
grouped into three age categories: aged 15–34 years, aged 35 to 44 years; and aged 45 years and
older because of the relationship of age to health outcomes that might result in differences in
the PPV within different age groups. All statistical analyses were conducted using Stata version
12.1 (Stata corporation, City, State) [13].
Ethical considerations
Ethical approval for the study was obtained from the Kenya Medical Research Institute and
United States Centers for Disease Control and Prevention.
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Fig 1. Inclusion of study subjects with clinical or immunological indication for viral load testing for
analysis. This figure describes how the subjects were excluded from this analysis. We excluded 1,119
pregnant women and 1,882 persons with unclear indications why VL testing was requested.
doi:10.1371/journal.pone.0158881.g001
Table 1. Contingency table used for calculating positive predictive value.
Virologic failure
Clinical or immunologic criteria present Yes No
Yes 1940 3703
No 934 5557
PPV = 1,940/(1,940+3703) = 34.4%.
doi:10.1371/journal.pone.0158881.t001
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Results
A total of 12,134 adult patient records were included in the analysis. The majority of patients
were receiving first-line ART; only 133, (1%) of patients were receiving second-line or subse-
quent regimens Table 2. The frequency distribution shows that there were more female patients
(61.6%) than male, that patients aged 35–44 years accounted for the largest aged group
(35.9%), and that most patients were seen at either a sub-district or district hospital (28.9% and
37.5%, respectively). There were a higher percentage of patients on second-line regimens aged
15 to 24 (6.0%) and aged over 54 years (13.5%) than those on first-line ART (3.8% and 11.5%
respectively). Over half of the patients (6354) 52.4% had missing CD4 cell counts in the period
90 days prior to or more than one week after the VL specimen was obtained and a few (45/
12,134) did not have CD4 value ever. Therefore, 6305 had CD4 values documented outside of
this period (data not shown). Of the 5,780 patients for whom we had CD4 data, 17.8% had
counts below 100 cells/ μL, 22.9% had cell counts between 100–199 cells/μL, 25.8% had counts
between 200–350 cells/μL, 15.3% had counts between 351–500 cells/μL and 18.3% had counts
above 500 cells/μL at the time of VL testing. Higher percentages of patients on second-line/
other ART regimen had CD4 cell counts< 100 cells/μL and between 100–199 cells/μL than
those on first-line treatment (18.8% and 15.8% vs 8.3% and 10.8%). Just over 10% of patients
had been on therapy for one year or less and most, (78.8%) had never changed regimens. Over
half of the patients on second-line therapy had been on ART for two years or less. Close to half
of the patients met both clinical and immunologic criteria, while 5,076 (41.8%) patients were
tested because of immunologic indications alone.
Of 12,134 patient specimens tested, 2,874 (23.7%) yielded an HIV RNA
concentration> 1000 copies/mL, confirming virologic treatment failure. Among those with
failure, the median RNA concentration was 41,150 copies/mL, interquartile range; 9,000–
133,800. The PPV for virologic failure among all ART patients who met either the clinical or
immunologic criteria for targeted VL testing was 34.4% (95% CI 33.1%-35.6%), 34.4% (95% CI
33.2%-35.7%) for first-line ART patients, and 33.1% (95% CI 24.7%-42.3% for patients who
were on second-line or other non-first-line regimens Table 3. Among patients who met clinical
but not immunologic criteria, the PPV for first-line ART patients was higher than the PPV for
second-line ART patients,36.5% (95% CI 33.7%-39.4%) and 21.6% (95% CI 9.83%-38.2%),
respectively. Among first-line ART patients, the PPVs dropped regardless of criteria category
among the older age groups.
Discussion
Less than a quarter of the over 12,000 patient specimens meeting clinical or immunologic crite-
ria for suspected treatment failure were confirmed to be failing treatment. The PPVs were
equally low for patients on second-line/other non-first-line ART compared to patients receiv-
ing first-line ART, which likely reflects the lack of specificity of clinical signs and symptoms.
Our findings are similar to those of other studies that have demonstrated poor PPV of either
clinical or immunologic criteria for ART failure but now extend the findings to include patients
receiving non-first-line regimens [5–7, 14–18]. As such, our findings provide additional evi-
dence of poor performance of the criteria to detect treatment failure. Indeed our results indi-
cate that if clinicians would have relied exclusively on the 2008 Kenya immunologic and
clinical criteria and classified these patients as treatment failures, over 75% of patients would
have been switched to new, more expensive, ART regimens unnecessarily.
Available evidence cannot support the use of clinical or immunologic criteria to accurately
identify virologic failure. Presently, there is no other, more effective strategy for assessing treat-
ment failure among ART patients than measuring their plasma viral levels [19]. Studies have
PPV of theWHOClinical and Immunologic Criteria to Predict VL Failure in Adults on 1st/2nd-Line ART
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Table 2. Characteristics of adults who underwent targeted viral load testing, Nyanza, Kenya, 2008–2011.




Men 4658(38.4) 4603(38.4) 55(41.4)
Women 7476(61.6) 7398(61.6) 78(58.6)
Age at VL testing (years)
15 to 24 459(3.8) 451(3.8) 8(6.0)
25 to 34 3153(26) 3118(26.0) 35(26.3)
35 to 44 4351(35.9) 4308(35.9) 43(32.3)
45 to 54 2777(22.9) 2748(22.9) 29(21.8)
55 to max 1394(11.5) 1376(11.5) 18(13.5)
Year VL test was done
2008 94 (0.8) 93(0.8) 1(0.8)
2009 407(3.4) 402(3.3) 5(3.8)
2010 3354(27.6) 3313(27.6) 41(30.8)
2011 8279(68.2) 8193(68.3) 86(64.7)
Facility
Dispensary/health center 2582(21.3) 2556(21.3) 26(19.5)
Sub-district hospital 3512(28.9) 3477(29.0) 35(26.3)
District hospital 4552(37.5) 4498(37.5) 54(40.6)
Provincial general hospital 84(0.7) 84(0.7) 0
Referral hospital 1404(11.6) 1386(11.5) 18(13.5)
CD4 at VL request
< 100 1027(8.5) 1002(8.3) 25(18.8)
100 to 199 1322(10.9) 1301(10.8) 21(15.8)
200 to 350 1494(12.3) 1477(12.3) 17(12.8)
351 to 500 882(7.3) 881(7.3) 1(0.8)
> 500 to max 1055(8.7) 1052(8.8) 3(2.3)
Missing 6354(52.4) 6288(52.4) 66(49.6)
Duration on ART (months)
6–12 1231(10.1) 1196(10.0) 35(26.3)
13–24 2751(22.7) 2714(22.6) 37(27.8)
25–36 2694(22.2) 2671(22.3) 23(17.3)
>37 4909(40.5) 4887(40.7) 22(16.5)
Missing 549(4.5) 533(4.4) 16(12)
Regimen changes
Never changed 9559(78.8) 9559(79.7) 0
Ever changed 2575(21.2) 2442(20.3) 133(100)
Indications for viral load testing
Clinical§ and immunologic|| criteria 6491(53.5) 6476(54.0) 15(11.3)
Clinical§ criteria only 567(4.7) 549(4.6) 18(13.5)
Immunological|| indications only 5076(41.8) 4976(41.5) 100(75.2)
*Includes nevirapine-based, efavirenz-based and two nucleotide-reverse transcriptase inhibitor regimens
† Includes protease inhibitor and lopinavir-based regimens
‡ Includes other non-first line regimens that not in listed in the Kenya treatment guidelines
§ WHO stage 3 or 4 condition and/or new or recurrent papular pruritic eruptions and six months or more of antiretroviral therapy
|| Persistent CD4 cell count <100 cells/μL and more than 12 months of antiretroviral therapy, or CD4 cell count rise of <50 cells/μL and more than 12 months
of antiretroviral therapy, or CD4 cell count rise of <50 cells/μL and more than 12 months of antiretroviral therapy, or CD4 cell count fall by >50% of peak and
six months or more of antiretroviral therapy.
doi:10.1371/journal.pone.0158881.t002
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demonstrated that dried blood spots (DBS) can be used to reliably and accurately quantify HIV
RNA concentrations for patients with high levels of viremia, but their performance at identify-
ing patients with lower VLs (e.g. between 1000–3000 copies/mL) is sub-optimal [20–22]. How-
ever, realizing this caveat of misclassification, using DBS as a source of specimens for
monitoring VLs in settings without other options for quantifying viral levels appears feasible in
many resource-constrained areas. A recent study compared VL measurements in adults and
children obtained from plasma and capillary blood DBS in Nyanza and Nairobi regions of
Kenya and found sensitivities greater than 87% and specificities greater than 94% for VLs of
1000 copies/mL or greater using DBS [23]. Applying these findings, in our study, DBS would
have optimally and correctly identified virologic treatment failure among 2,564 (89.2%) of
patient specimens who had VL greater than 3000 copies/mL.
A major strength of our data is that they originate from routine HIV care facilities and
reflect clinicians’ suspicions of patients with treatment failure. Our data provide additional evi-
dence for the poor performance of clinical and immunologic criteria to detect treatment failure
regardless of the ART regimen, but there are limitations to consider. Because our specimens
came from patients who were receiving routine HIV care and met at least one of the criteria for
targeted VL testing, we were unable to calculate the negative predictive value. In addition to
our study being limited by the patient selection, the data came from one region in Kenya and
may not be representative of other areas of the country or elsewhere. Furthermore, the infor-
mation regarding patients came exclusively from laboratory requisition forms and is limited in
scope. Over half of the patients did not have CD4 data due to the asynchronous collection of
Table 3. Positive predictive value (PPV) of clinical and immunologic criteria for identifying treatment failure among HIV-infected adults receiving
first-line or second-line/other antiretroviral therapy, Nyanza Province, 2008–2011.








n(%) PPV% (95% CI) PPV% (95% CI) PPV% (95% CI)
Any regimen (N = 12134)
Total 2874(23.7) 34.4(33.1–35.6) 36.0(33.3–38.8) 35.5(34.2–36.8)
Age at viral load testing (years)
15 to 34 1134(31.4) 45.5(43.1–47.9) 44.5(39.5–49.7) 47.2(44.7–49.8)
35 to 44 995(22.9) 33.6(31.5–35.8) 35.0(30.4–39.8) 34.8(32.6–37.1)
45 to oldest 745(17.9) 25.4(23.5–27.4) 28.3(23.7–33.2) 26.0(23.9–28.1)
Patients receiving first-line antiretroviral
therapy (n = 12001)
Total 2834(23.6) 34.4(33.2–35.7) 36.5(33.7–39.4) 35.5(34.2–36.8)
Age at viral load testing (years)
15 to 34 1118(31.3) 45.6(43.2–48.0) 45.6(40.5–50.8) 47.3(44.7–49.8)
35 to 44 984(22.8) 33.7(31.6–35.9) 35.0(30.4–39.9 35.0(32.7–37.3)
45 to oldest 732(17.8) 25.3(23.3–27.3) 28.4(23.8–33.4) 25.9(23.8–28.0)
Patients on second-line/other non-first-
line ART (n = 133)
Total 40(30.1) 33.1(24.7–42.3) 21.6(9.83–38.2) 35.0(25.7–45.2)
Age at viral load testing (years)
15 to 34 16(37.2) 41.0(25.6–57.9) 0.0(0.0–33.6) 45.7(28.8–63.4)
35 to 44 11(25.6) 27.5(14.6–43.9) 33.3(9.9–65.1) 27.3(13.3–45.5)
45 to oldest 13(27.7) 30.8(17.0–47.6) 25.0(7.3–52.4) 31.3(16.1–50.0)
*Viral load1000 copies/mL.
doi:10.1371/journal.pone.0158881.t003
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CD4 and VL samples. Since the guidelines state that patients with poor adherence two weeks
prior to VL testing, active infections, fever, or newly diagnosed with tuberculosis should not be
tested for virologic failure, we were not able to verify if patients with some of these criteria were
indeed failing treatment. The number of specimens from patients receiving non-first-line ART
was small and resulted in less precise estimates that those obtained for patients on first-line
ART; larger samples may have produced different results.
Our results indicate that the 2008 Kenya immunologic and clinical criteria may have mis-
classified too many persons as cases of suspected treatment failure and support the incorpo-
ration of routine VL testing as a component of ART monitoring in the Kenyan national
treatment guidelines so as to prevent expensive unnecessary ART regimen changes. Younger
patients had a higher proportion of treatment failure. It is important to closely monitor this
dynamic population since they have more years of ART ahead of them. We also found that the
sensitivity was lower for older persons who are at higher risk for a number of other, non-HIV-
related conditions whose symptoms may be misclassified as indicators for viral load testing rel-
ative to younger persons. While we did find that the PPVs were slightly better for first-line regi-
mens, they were still too poor to recommend continued use of targeted VL testing. As Kenya
implements new guidelines on routine VL testing, careful attention will be needed to ensure
that health workers are appropriately trained and processes developed for tracking samples
and updating results in patient charts. It will be important to establish close monitoring and
assess the impact of this change in clinical management. Routine VL data will eventually be
useful addition to HIV case-based surveillance.
Supporting Information
S1 Data. Data used in the analysis. This file contains Stata data used for these analyses.
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